MA51418A - Inhibiteurs de glycolate oxydase pour le traitement de maladies - Google Patents

Inhibiteurs de glycolate oxydase pour le traitement de maladies

Info

Publication number
MA51418A
MA51418A MA051418A MA51418A MA51418A MA 51418 A MA51418 A MA 51418A MA 051418 A MA051418 A MA 051418A MA 51418 A MA51418 A MA 51418A MA 51418 A MA51418 A MA 51418A
Authority
MA
Morocco
Prior art keywords
diseases
treatment
oxidase inhibitors
glycolate oxidase
glycolate
Prior art date
Application number
MA051418A
Other languages
English (en)
Inventor
Qi Chao
Bing Wang
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of MA51418A publication Critical patent/MA51418A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
MA051418A 2017-12-29 2018-12-28 Inhibiteurs de glycolate oxydase pour le traitement de maladies MA51418A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762611995P 2017-12-29 2017-12-29
US201862765313P 2018-08-20 2018-08-20

Publications (1)

Publication Number Publication Date
MA51418A true MA51418A (fr) 2020-11-04

Family

ID=65234672

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051418A MA51418A (fr) 2017-12-29 2018-12-28 Inhibiteurs de glycolate oxydase pour le traitement de maladies

Country Status (17)

Country Link
US (3) US11384055B2 (fr)
EP (1) EP3732167A2 (fr)
JP (2) JP7344878B2 (fr)
KR (1) KR20200112860A (fr)
CN (6) CN117126152A (fr)
AR (1) AR114070A1 (fr)
AU (1) AU2018395275A1 (fr)
BR (1) BR112020013073A2 (fr)
CA (1) CA3086401A1 (fr)
CL (1) CL2020001742A1 (fr)
IL (3) IL297802A (fr)
MA (1) MA51418A (fr)
MX (6) MX2020006414A (fr)
PE (1) PE20201500A1 (fr)
SG (1) SG11202005807QA (fr)
TW (2) TW202340155A (fr)
WO (1) WO2019133770A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202340155A (zh) * 2017-12-29 2023-10-16 美商拜奧馬林製藥公司 用於疾病治療之乙醇酸酯氧化酶抑制劑
US11389456B2 (en) 2018-02-23 2022-07-19 Oxalurx, Inc. Compounds and methods for treating oxalate-related diseases
KR20210041564A (ko) * 2018-07-06 2021-04-15 오판 바이오테크 인코포레이티드 트리아졸 글리콜레이트 옥시다아제 억제제
EP4017490A4 (fr) * 2019-08-22 2023-11-22 Oxalurx, Inc. Composés et méthodes de traitement de maladies liées à l'oxalate
CA3155577A1 (fr) * 2019-11-01 2021-05-06 GyanRx Sciences, Inc. Carboxylates heterocycles en tant qu'inhibiteurs de glycolate oxydase
AU2021205916A1 (en) * 2020-01-08 2022-08-25 Cantero Therapeutics, Inc. Processes for preparing triazole glycolate oxidase inhibitors
WO2022002131A1 (fr) * 2020-06-30 2022-01-06 苏州恩华生物医药科技有限公司 Dérivé de 5-((1,2,3,4-tétrahydroisoquinoline-7-yl)amino)pyridin-2(1h)-one et son utilisation
WO2022066933A1 (fr) * 2020-09-24 2022-03-31 Chinook Therapeutics Canada, Inc. Composés triazolyl substitués de pentafluoro-sulfanyl et procédés d'utilisation associés
CN114478210A (zh) * 2022-02-26 2022-05-13 江苏壹药新材料有限公司 一种7-氯萘-2-甲醛的合成方法
WO2023170024A1 (fr) * 2022-03-11 2023-09-14 University Of Copenhagen Modulateurs de camk2 et leur utilisation en médecine
GB202213162D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Prodrugs

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US149223A (en) * 1874-03-31 Improvement in axles for vehicles
DE2860722D1 (en) * 1977-11-10 1981-08-27 Beecham Group Plc Triazolo-quinoline derivatives, processes for their preparation and their pharmaceutical use
DE2757929A1 (de) * 1977-12-24 1979-07-05 Boehringer Sohn Ingelheim Neue pyrido-eckige klammer auf 1,2-a eckige klammer zu -v-triazolo- eckige klammer auf 4,5-d eckige klammer zu pyrimidinone, deren salze und verfahren zu deren herstellung
JPS5519292A (en) * 1978-07-24 1980-02-09 Beecham Group Ltd Benzopyranotriazoles*their manufacture and medical composition containing them
DE2966444D1 (en) 1978-07-24 1984-01-05 Beecham Group Plc Benzopyranotriazoles, preparation of these compounds and pharmaceutical composition containing them
US4431660A (en) 1979-06-11 1984-02-14 Merck & Co., Inc. (4'-Biphenylyloxy and-thio-oxy)-3-hydroxy-3-pyrroline-2,5-diones and a method of treating calcium oxalate renal lithiasis therewith
US4349561A (en) * 1979-11-05 1982-09-14 Merck & Co., Inc. 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
DE3169772D1 (de) * 1980-01-19 1985-05-15 Beecham Group Plc Substituted benzopyranotriazoles
IL61897A (en) * 1980-01-19 1984-01-31 Beecham Group Ltd Benzopyrano(2,3-d)-v-triazoles,their production and pharmaceutical compositions containing them
NZ199139A (en) * 1980-12-13 1985-01-31 Beecham Group Ltd Benz(phenoxyalkoxy)-9-oxo-1h,9h-benzopyrano-(2,3-d)-v-triazoles
US4431652A (en) 1980-12-29 1984-02-14 Merck & Co., Inc. 4-Hydroxy-5-substituted-3(2H)-isothiazolone-1,1-dioxide derivatives useful in treating urinary tract calcium oxalate lithiasis
US4428956A (en) * 1980-12-29 1984-01-31 Merck & Co., Inc. 4-Hydroxy-5-substituted-3-(2H)-isothiazolone-1,1-dioxide derivatives useful in treating urinary tract calcium oxalate lithiasis
JPS57158788A (en) * 1981-03-03 1982-09-30 Beecham Group Ltd Novel compound, manufacture and medicinal composition containing same
WO1993017681A1 (fr) * 1992-03-02 1993-09-16 Abbott Laboratories Antagonistes du recepteur d'angiotensine ii
US6962936B2 (en) * 2001-04-27 2005-11-08 Vertex Pharmaceuticals Incorporated Triazole-derived kinase inhibitors and uses thereof
JP4075357B2 (ja) 2001-11-15 2008-04-16 宇部興産株式会社 ４，５−ジ置換−１，２，３−トリアゾール及びその製造法
BR0317230A (pt) * 2002-12-13 2005-10-25 Smithkline Beecham Corp Composto, composição, métodos de antagonizar uma atividade do receptor de quimiocina ccr-5, e de tratar uma infecção viral em um paciente, e, uso de um composto
GB0329214D0 (en) * 2003-12-17 2004-01-21 Glaxo Group Ltd Novel compounds
GB0603891D0 (en) * 2006-02-27 2006-04-05 Syngenta Ltd Novel herbicides
WO2011140296A1 (fr) * 2010-05-05 2011-11-10 Infinity Pharmaceuticals Triazoles utilisés comme inhibiteurs d'acides gras synthase (fasn)
IN2014DN09348A (fr) * 2012-06-20 2015-07-17 Hoffmann La Roche
KR101537296B1 (ko) * 2012-10-26 2015-07-17 삼성전자 주식회사 반도체 나노결정 및 그 제조방법
TW201418242A (zh) 2012-10-26 2014-05-16 Du Pont 作為除草劑之經取代的***
JP2017095366A (ja) 2015-11-18 2017-06-01 持田製薬株式会社 新規ビアリールアミド誘導体
US20200262794A1 (en) 2015-12-07 2020-08-20 Wake Forest University Health Sciences Glycolate oxidase inhibitors and methods of use for the treatment of kidney stones
CN105541796B (zh) 2016-03-03 2017-11-14 武汉工程大学 一种nh‑1,2,3‑***联吡啶化合物的合成方法
CN105669569B (zh) 2016-03-03 2017-12-12 武汉工程大学 一种nh‑1,2,3‑***化合物的合成方法
TW202340155A (zh) * 2017-12-29 2023-10-16 美商拜奧馬林製藥公司 用於疾病治療之乙醇酸酯氧化酶抑制劑
BR112021025781A2 (pt) * 2019-06-19 2022-03-03 Biomarin Pharm Inc Composto, composição farmacêutica, método de tratamento de uma doença ou transtorno associado com um defeito no metabolismo de glioxilato, método de tratamento de uma doença ou transtorno associado com a enzima glicolato oxidase (go) ou alterações no metabolismo de oxalato e método para inibição da enzima go

Also Published As

Publication number Publication date
WO2019133770A3 (fr) 2019-08-15
IL297788A (en) 2022-12-01
JP7344878B2 (ja) 2023-09-14
JP2021509401A (ja) 2021-03-25
RU2020120974A (ru) 2022-01-31
EP3732167A2 (fr) 2020-11-04
PE20201500A1 (es) 2020-12-29
TW201930272A (zh) 2019-08-01
TWI811282B (zh) 2023-08-11
MX2020006414A (es) 2020-09-17
WO2019133770A2 (fr) 2019-07-04
IL297802A (en) 2022-12-01
IL275496A (en) 2020-08-31
AU2018395275A1 (en) 2020-07-16
RU2020120974A3 (fr) 2022-01-31
CN117024420A (zh) 2023-11-10
MX2022016427A (es) 2023-01-30
CN117126151A (zh) 2023-11-28
CL2020001742A1 (es) 2021-01-29
US20230089374A1 (en) 2023-03-23
BR112020013073A2 (pt) 2020-12-01
CN117126152A (zh) 2023-11-28
CN111788187A (zh) 2020-10-16
CN117069712A (zh) 2023-11-17
US20230079913A1 (en) 2023-03-16
US11384055B2 (en) 2022-07-12
KR20200112860A (ko) 2020-10-05
TW202340155A (zh) 2023-10-16
US20210171474A1 (en) 2021-06-10
JP2023159181A (ja) 2023-10-31
MX2022016434A (es) 2023-01-30
CA3086401A1 (fr) 2019-07-04
AR114070A1 (es) 2020-07-15
MX2022016415A (es) 2023-01-30
CN117069713A (zh) 2023-11-17
MX2022016422A (es) 2023-01-30
SG11202005807QA (en) 2020-07-29
MX2022016463A (es) 2023-02-01

Similar Documents

Publication Publication Date Title
MA51418A (fr) Inhibiteurs de glycolate oxydase pour le traitement de maladies
MA49144A (fr) Polythérapies pour le traitement du cancer
MA49767A (fr) Conjugués de cytokine pour le traitement de maladies auto-immunes
FR3046933B1 (fr) Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
MA55974A (fr) Composés triaryles pour le traitement de maladies pd-l1
MA47719A (fr) Esketamine pour le traitement de la dépression
MA55325A (fr) Composés pour le traitement de maladies pd-l1
MA55629A (fr) Compositions d'anticorps pour le traitement de tumeurs
MA48637A (fr) Polythérapies pour le traitement du cancer
MA41449A (fr) Polythérapies pour le traitement de cancers
MA50409A (fr) Polythérapies pour le traitement du cancer
IL279260A (en) KDM1A inhibitors for the treatment of diseases
MA43000A (fr) Polythérapie pour le traitement de tumeurs malignes
MA51139A (fr) Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer
IL264048A (en) pde9 inhibitors for the treatment of peripheral diseases
MA54925A (fr) Compositions pour le traitement de troubles acido-basiques
MA47604A (fr) Anticorps anti-pd-1 pour le traitement du cancer du poumon
MA41299A (fr) Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite
MA56412A (fr) Thérapie par l'arn messager pour le traitement des maladies articulaires
MA42999A (fr) Polythérapie pour le traitement de malignités
IL288920A (en) Glycolate oxidase inhibitors for the treatment of diseases
MA53614A (fr) Protéine pour le traitement de maladies inflammatoires
MA45973A (fr) Combinaisons d'inhibiteurs de btk pour le traitement du myélome multiple
MA43800A (fr) Octréotide par voie orale pour le traitement de maladies